Global Health Limited has received an ESG rating of 69 for Financial Year 2025 from NSE Sustainability Ratings & Analytics Limited, the company announced through a regulatory filing on February 20, 2026.

Regulatory Compliance and Filing Details

The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company filed the intimation with both major stock exchanges where its shares are listed.

Stock Exchange Communication

The formal communication was addressed to both BSE Limited and National Stock Exchange of India Limited. The company trades under scrip code 543654 on BSE and symbol MEDANTA on NSE. The filing ensures compliance with regulatory requirements for disclosure of material information to investors and stakeholders.

Corporate Governance

The regulatory filing was executed by Rahul Ranjan, Company Secretary & Compliance Officer (Membership No. A17035), who digitally signed the document on February 20, 2026, at 13:11:03 +05'30'. The communication emphasized that this information is provided for the exchanges' information and record purposes.

ESG ratings assess companies on environmental, social, and governance parameters, providing investors and stakeholders with insights into corporate sustainability practices and responsible business conduct.

Global Health Limited announced its unaudited financial results for the third quarter ended December 31, 2025, showcasing strong revenue growth while facing significant challenges from exceptional items related to new Labour Code implementation. The healthcare company's Board of Directors approved the quarterly results at their meeting held on February 04, 2026.

Strong Revenue Performance Continues

The company delivered robust consolidated revenue growth, achieving ₹11.21 billion in Q3FY26 compared to ₹9.43 billion in the corresponding quarter of the previous year. This represents a significant year-on-year growth of 18.8%, demonstrating the company's continued ability to expand its healthcare services despite operational challenges. On a standalone basis, revenue from operations reached ₹9.40 billion compared to ₹8.12 billion in Q3FY25.

Profitability Impacted by Labour Code Implementation

Despite strong top-line performance, the company's profitability faced headwinds during the quarter. Consolidated profit before exceptional items stood at ₹1.56 billion, down from ₹1.89 billion in Q3FY25, representing a 17.5% decline. The quarter was significantly impacted by exceptional items worth ₹366 million on a consolidated basis, primarily related to the implementation of new Labour Codes.

Labour Code Implementation Creates One-Time Impact

The most significant factor affecting Q3FY26 results was the implementation of new Labour Codes notified by the Government of India on November 21, 2025. These codes consolidated 29 existing labour laws and resulted in an exceptional charge of ₹352 million for the standalone entity and ₹366 million on a consolidated basis. This charge relates to incremental provisions for gratuity and compensated absences based on the new regulatory framework.

Board Decisions and Corporate Developments

Beyond financial results, the Board approved several key appointments and recommendations. Mr. Malik Mohd. Ashhab was appointed as Head-Diagnostic Services, bringing over 16 years of diagnostics sector experience to lead the Retail Lab Business of the Group. The Board also recommended re-appointments of Dr. Ravi Gupta and Mr. Rajan Bharti Mittal as Independent Directors for second terms of five years each, along with the appointment of Ms. Shonan Purie Trehan as a Non-Executive Non-Independent Director.

Operational Expansion and Future Outlook

The company continues its expansion efforts, having received physical possession of 3.5 acres of land from Assam Industrial Development Corporation Limited during Q3FY26. Additionally, the company granted 605,500 stock options to eligible employees under its long-term incentive plan, demonstrating continued investment in talent retention and motivation.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, consolidated revenue reached ₹32.51 billion compared to ₹27.61 billion in the corresponding period last year, marking an 17.8% growth. Consolidated net profit for the nine-month period stood at ₹4.12 billion versus ₹3.80 billion in the previous year, showing resilience despite quarterly challenges.